We recruited outstanding PhD classes in Biomedical Sciences and Neuroscience—the most diverse in our history: 27 percent are from racial and ethnic backgrounds underrepresented in science; 66.7 percent are women; and 29 percent are first-generation college graduates.
We received accreditation by the New York State Education Department for a new PhD concentration, Artificial Intelligence and Emerging Technologies in Medicine, for enrollment in fall 2022.
We created bold initiatives that will reinforce Mount Sinai’s national leadership in diversity and inclusion. These included refocusing the Summer Undergraduate Research Program on underrepresented students (SURP4US).
The stand-alone medical school we support with our research activities, the Icahn School of Medicine at Mount Sinai, is ranked No. 17 in the nation by U.S. News & World Report. Together, we are embedded in the Mount Sinai Health System, New York City’s largest.
We received $440.1 million in total National Institutes of Health (NIH) funding, No. 14 in the nation for fiscal year 2021. Our Department of Microbiology’s global leadership in pathogen research reached new heights when it received a $42 million award for basic research into influenza and SARS-CoV-2, and for the surveillance of emerging pathogens. The contract builds on seminal work and represents 21 years of continuity in funding, which will also support the training of Mount Sinai’s postdoctoral fellows and students.
We expanded external partnerships for research and course exchanges with The Cooper Union for the Advancement of Science and Art; the Hasso Plattner Institute; and Rensselaer Polytechnic Institute (RPI), creating a Life Sciences Entrepreneurship Certificate in RPI’s MBA program.
We became an official member of the National Science Foundation Innovation Corps (NSF I-Corps) Hub: New York Region, an academic consortium that aims to develop and disseminate best practices and expertise in customer and industry discovery for the translation of innovations into viable products that benefit society.
In this Report, you can learn more about our strengths, which include the unparalleled opportunities our outstanding faculty offer to our PhD students so they excel at every level of their training.
With considerable optimism for 2022, we expect our faculty, students, and trainees will reach new milestones in science and education. This is who we are.
Marta Filizola, PhD
Dean of the Graduate School of Biomedical Sciences, the Sharon & Frederick A. Klingenstein/Nathan G. Kase, MD Professor of Pharmacological Sciences, Professor of Neuroscience, and Professor of Artificial Intelligence and Human Health